

**MHS PHARMACY BENEFIT  
NARCOLEPSY AGENTS PRIOR AUTHORIZATION REQUEST FORM**

MHS  
550 N. Meridian St. Suite 101  
Indianapolis, IN, 46204-1208  
Phone: (877) 647-4848 Fax: (866) 399-0929



Today's Date

□□ / □□ / □□□□

**Note:** This form must be completed by the prescribing provider.

**\*\*All sections must be completed or the request will be returned\*\***

Patient's Medicaid #	□□□□□□□□□□	Date of Birth	□□ / □□ / □□□□
Patient's Name	Prescriber's Name		
Prescriber's IN License #	□□□□□□□□	Specialty	
Prescriber's NPI #	□□□□□□□□□□	Prescriber's Signature	
Return Fax #	□□□□ - □□□□ - □□□□	Return Phone #	□□□□ - □□□□ - □□□□
Check box if requesting retro-active PA	<input type="checkbox"/>	Date(s) of service requested for retro-active eligibility (if applicable):	

*Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).*

Requested Medication	Quantity	Dosing

**PA Requirements for Nuvigil (armodafinil):**

The member is 18 years of age or older and has one of the following diagnoses:

- Bipolar depression in conjunction with appropriate medical intervention(s)
  - List any other medical intervention(s) being utilized for bipolar depression (e.g., mood stabilizers):  
\_\_\_\_\_
- Narcolepsy with excessive daytime sleepiness
- Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)
  - List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?  
\_\_\_\_\_
- Shift work sleep disorder

**PA Requirements for Provigil (modafinil):**

Select ONE of the following:

- 1) The member is 6 years of age or older and has one of the following diagnoses:
  - Attention deficit hyperactivity disorder (ADHD)
  - Narcolepsy with excessive daytime sleepiness
- 2) The member is 18 years of age or older and has one of the following diagnoses:
  - Depression-related fatigue in conjunction with appropriate medical intervention(s)
    - List any other medical intervention(s) being utilized for depression (e.g., antidepressants):  
\_\_\_\_\_
  - Idiopathic hypersomnia
  - Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)
    - List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?  
\_\_\_\_\_
  - Shift work sleep disorder
  - Sleep deprivation
  - Steinert myotonic dystrophy syndrome
  - Unipolar or bipolar depression in conjunction with appropriate medical intervention(s)
    - List any other medical intervention(s) being utilized for unipolar/bipolar depression (e.g., antidepressants/mood stabilizers):  
\_\_\_\_\_

**PA Requirements for Sunosi (solriamfetrol):**

The member is 18 years of age or older and has one of the following diagnoses:

- Narcolepsy with excessive daytime sleepiness
- Obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)
  - List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?  
\_\_\_\_\_

- Has the member had a previous trial and failure with any of the following in the past year:

Modafinil            Dates of use: \_\_\_\_\_

Armodafinil        Dates of use: \_\_\_\_\_

If no, please provide any other medical justification for use: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**PA Requirements for Wakix (pitolisant):**

Select ONE of the following:

- The member is 6 years of age or older and has a diagnosis of narcolepsy with cataplexy or excessive daytime sleepiness
- The member is 18 years of age or older and has a diagnosis of obstructive sleep apnea/hypopnea syndrome with residual excessive daytime sleepiness in conjunction with appropriate medical intervention(s)

- List any other medical intervention(s) being utilized for obstructive sleep apnea (e.g., PAP, OPT, etc.)?  
\_\_\_\_\_

- Has the member had a previous trial and failure with any of the following in the past year:

Modafinil            Dates of use: \_\_\_\_\_

Armodafinil        Dates of use: \_\_\_\_\_

If no, please document any other medical justification for use: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**PA Requirements for Xyrem (sodium oxybate):**

**Initial Authorization**

Select ONE of the following:

- 1) The member is 7 years of age or older and has narcolepsy with cataplexy or excessive daytime sleepiness diagnosis  Yes     No

- Please provide requested dose per day: \_\_\_\_\_
- Please provide member's weight (include date of collection): \_\_\_\_\_

- 2) The member is 18 years of age or older and has fibromyalgia diagnosis  Yes     No

- Has the member had a previous trial and failure with ONE of the following?

Amitriptyline                          Dates of use: \_\_\_\_\_

SSRIs    Medication name and dates of use:  
\_\_\_\_\_

SNRIs    Medication name and dates of use:  
\_\_\_\_\_

Anticonvulsants  
(gabapentin, pregabalin)                          Medication name and dates of use:  
\_\_\_\_\_

NSAIDs and APAP                          Dates of use: \_\_\_\_\_

If member has not trialed all of the above agents, please provide medical justification as to why that agent or an agent in that class was not trialed.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

- Please provide requested dose per day: \_\_\_\_\_

**Reauthorization**

- 1) Please provide the following information showing an attempt to decrease dose or trial and failure of an alternative therapy within the past year:
  - Date of dose reduction attempt: \_\_\_\_\_
  - Original dose member was prescribed: \_\_\_\_\_
  - Dose member was reduced to: \_\_\_\_\_
  - Outcomes of dose reduction: \_\_\_\_\_
  - Trial and failure of an alternative therapy (name of medication, date of trial, and an explanation as to how the member failed):  
\_\_\_\_\_  
\_\_\_\_\_
  
- 2) Please provide documentation showing continued benefit from the medication (i.e., reduction in frequency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without significant adverse events (documentation must include most recent chart notes)

**PA Requirements for Xywav (calcium/magnesium/potassium/sodium oxybates solution):**

**Initial Authorization**

Select ONE of the following:

- 1) The member is 7 years of age or older and has narcolepsy with cataplexy or excessive daytime sleepiness diagnosis  Yes  No
  - Please provide requested dose per day: \_\_\_\_\_
  - Please provide member's weight (include date of collection): \_\_\_\_\_
  
- 2) The member is 18 years of age or older has idiopathic hypersomnia  Yes  No
  - Please provide requested dose per day: \_\_\_\_\_

**Reauthorization**

- 1) Please provide the following information showing an attempt to decrease dose or trial and failure of an alternative therapy within the past year:
  - Date of dose reduction attempt: \_\_\_\_\_
  - Original dose member was prescribed: \_\_\_\_\_
  - Dose member was reduced to: \_\_\_\_\_
  - Outcomes of dose reduction: \_\_\_\_\_
  - Trial and failure of an alternative therapy (name of medication, date of trial, and an explanation as to how the member failed):  
\_\_\_\_\_  
\_\_\_\_\_
  
- 2) Please provide documentation showing continued benefit from the medication (i.e., reduction in frequency of cataplexy, reduction in symptoms of excessive daytime sleepiness, etc.) without significant adverse events (documentation must include most recent chart notes)

**CONFIDENTIAL INFORMATION**

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.